Prithviraj Bose, MD

Prithviraj Bose, MD, associate professor, The University of Texas MD Anderson Cancer Center, discusses differences in the safety profiles of ruxolitinib (Jakafi) and fedratinib (Inrebic) in the treatment of myelofibrosis.

Bose believes ruxolitinib and fedratinib are similar in terms of efficacy and toxicity. Looking at ruxolitinib in the COMFORT trial and fedratinib in the JAKARTA trial, the rate of spleen volume reduction, total symptom score reduction and the incidence of&nbsp;the main adverse events, including anemia, and thrombocytopenia, are comparable, according to Bose.

Videos

Prithviraj Bose, MD, discusses differences in the safety profiles of ruxolitinib and fedratinib in the treatment of myelofibrosis.

Safety Profiles of Ruxolitinib and Fedratinib in Myelofibrosis

Prithviraj Bose, MD, an associate professor in the Department of Leukemia, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, discusses a study exploring sotatercept (ACE-011) alone and in combination with ruxolitinib (Jakafi) in patients with myeloproliferative neoplasm (MPN)-associated myelofibrosis and anemia.

This single-arm, open-label, phase II trial included 2 cohorts of patients, with one receiving sotatercept alone, and the other receiving sotatercept added to ruxolitinib.

Prithviraj Bose, MD, an associate professor in the Department of Leukemia, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, discusses a study exploring sotatercept (ACE-011) alone and in combination with ruxolitinib (Jakafi) in patients with myeloproliferative neoplasm (MPN)-associated myelofibrosis and anemia.&nbsp;

Prithviraj Bose, MD | Authors

Articles

Safety Profiles of Ruxolitinib and Fedratinib in Myelofibrosis

A Study Exploring Sotatercept and Ruxolitinib in MPN-Associated Myelofibrosis and Anemia